• Corpus ID: 1196825

Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1.

@article{Hookes2010AssociationFR,
  title={Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1.},
  author={Livia Hookes},
  journal={IDrugs : the investigational drugs journal},
  year={2010},
  volume={13 7},
  pages={
          427-9
        }
}
  • L. Hookes
  • Published 1 July 2010
  • Medicine
  • IDrugs : the investigational drugs journal
The 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Fort Lauderdale, FL, USA, included topics covering new therapeutic developments in the field of eye and vision research. This conference report highlights selected presentations on the development of FOV-2304 (Fovea Pharmaceuticals SA) for the potential treatment of diabetic macular edema; PHA-666859 (Pfizer Inc) for diabetic retinopathy; GTx-878 (GTx Inc) and FCFD-4514S (Genentech Inc) for age… 
Diabetic retinopathy: Breaking the barrier.
Retinal Physiology and Circulation: Effect of Diabetes.
TLDR
Several alterations in the retinal circulation occurring earlier in the progression of disease are focused on, including reductions in blood flow and a possible redistribution of perfusion that may leave some areas of the retina ischemic and hypoxic.
The assessment of the concentration of candidate cytokines in response to conjunctival-exposure of atmospheric low-temperature plasma in an animal model
TLDR
ALTP can probably be used as a minimally-invasive therapeutic method that triggers no permanent or continual inflammatory responses and might help the patients to shorten the consumption of immunosuppressive drugs after ALTP-surgery.